GlassScriptPhysician profile
Rahn K Bailey
NPI 1063565737
$7,910.32
in general payments reported to CMS, 2019-2025
21 companies · $971 in 2025
The $971 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $1,371 · 2021: $2,361 · 2022: $551 · 2023: $1,078 · 2024: $1,023 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,018.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $1,314.34 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $1,164.05 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $614.94 | 2023-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $422.06 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Sage Therapeutics, LLC | $384.59 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $297.65 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $216.11 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $206.31 | 2025 | Cobenfy |
| Biogen, INC. | $170.77 | 2023 | |
| Neurocrine Biosciences, INC. | $160.04 | 2020-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $153.65 | 2024-2025 | Auvelity |
| Abbvie INC. | $140.99 | 2024-2025 | |
| Luye Pharma (USA) LTD. | $140.40 | 2025 | Erzofri Extended-Release |
| Tg Therapeutics, INC. | $124.99 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $124.76 | 2022 | |
| Viiv Healthcare Company | $108.01 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.10 | 2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $39.91 | 2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $30.38 | 2024 | Abilify Maintena |
| Ucb, INC. | $20.54 | 2023 | Briviact |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahn Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.